Cyclophosphamide in the treatment of multiple myeloma
| Autor: | W. J. Kaipainen, S. J. Salokannel, I. P. Palva, T. Timonen |
|---|---|
| Rok vydání: | 1971 |
| Předmět: |
Male
Melphalan medicine.medical_specialty Cyclophosphamide Disease Asymptomatic Sex Factors Internal medicine medicine Humans Finland Multiple myeloma Hematology business.industry General Medicine Middle Aged Prognosis medicine.disease Surgery Female medicine.symptom Acidosis Multiple Myeloma Complication business Median survival medicine.drug |
| Zdroj: | Blut Zeitschrift für die Gesamte Blutforschung. 23:129-132 |
| ISSN: | 1432-0584 0006-5242 |
| Popis: | The median survival period for 19 patients with multiple myeloma treated with cyclophosphamide was 22 months. This is about the same as the best earlier results in the treatment of myelomatosis with cyclophosphamide or melphalan. No differences were seen between the survival periods, of male and female patients. Many patients experienced relief of bone pains and became asymptomatic although objective signs of the disease regressed only slightly. The significance of azotaemia as a sign of unfavourable prognosis is striking in the present series. Both of the two initially azotaemic patients died during their first month of treatment. A record of azotaemic later in the course of the disease was similarly, associated with a rapid deterioration and death. However, as the survival period of the patients who later became azotaemic was no shorter than that of the whole group, it seems more likely that azotaemia is a natural phase in the course of myelomatosis rather than a complication of cytostatic therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink